Peptide Library

Every completed file. Every planned name. Clearly separated.

Browse 28 checked evidence files A–Z, start with a question, or see the 22 names still in the research queue. A name in the queue is not a profile, conclusion, or recommendation.

28 + 22

28 completed evidence files are public and linked below. 22 planned names appear later only so the coverage roadmap is transparent. They have no evidence summary or publication status beyond “researching.”

28 completed · 22 researching

Start with what you want to understand

This is guided learning, not a treatment quiz. Choose a question to filter the completed evidence files; PepCurrent does not choose a peptide for you.

The rule: these routes organize evidence questions. They do not rank compounds, diagnose, or say what helps an individual reader.

Completed evidence files · A–Z

All 28 are visible by default. The approval or regulatory boundary comes before the name; the short answer comes from the reviewed Library content.

Completed evidence fileNot FDA-approved

AOD-9604

The largest study in FDA's review enrolled 536 people and did not beat placebo on weight loss.

Also searched as: fat-loss peptide

Open the evidence file →

Completed evidence filePCAC recommended inclusion · FDA final action pending

BPC-157

One 12-person uncontrolled study is the entire human musculoskeletal record identified in the cited review. PCAC recommended inclusion; FDA final action remains pending.

Also searched as: body protection compound · recovery peptide

Open the evidence file →

Completed evidence fileNarrow FDA approval

Bremelanotide / PT-141

One narrow FDA approval is real. Broad claims for men, postmenopausal women, and performance are not the approved use.

Also searched as: PT-141 · libido peptide

Open the evidence file →

Completed evidence fileInvestigational

Cagrilintide / CagriSema

Defined cagrilintide and semaglutide study products have phase 3 evidence. The proposed fixed-dose product is submitted, not approved, and the results do not authenticate unrelated products.

Also searched as: CagriSema · cagrilintide

Open the evidence file →

Completed evidence fileNo FDA-approved product

CJC-1295 + Ipamorelin

Real GH/IGF-1 elevation, measured in people. Zero human trial of the actual stack. WADA-banned.

Also searched as: CJC-1295 · ipamorelin · CJC ipa

Open the evidence file →

Completed evidence fileWithdrawn compounding nomination · advisory review announced

Dihexa

No administered-human evidence was identified; two central mechanism papers are retracted and a third carries a notice of concern.

Also searched as: Dihexa acetate · ATH-1001 · PNB-0408 · cognition peptide

Open the evidence file →

Completed evidence fileNarrow FDA accelerated approval

Elamipretide / Forzinity

A real accelerated approval for a narrow Barth syndrome population—not an anti-aging or general-energy approval.

Also searched as: SS-31

Open the evidence file →

Completed evidence filePCAC recommended against inclusion · FDA final action pending

Emideltide / DSIP

Small intravenous studies from the 1980s exist, but FDA calls the insomnia evidence inconclusive and preliminary.

Also searched as: DSIP · delta sleep-inducing peptide

Open the evidence file →

Completed evidence filePCAC recommended inclusion · FDA final action pending

Epitalon

One narrow human biomarker study does not demonstrate insomnia treatment, age reversal, or longer life.

Also searched as: epithalon

Open the evidence file →

Completed evidence fileCosmetic ingredient context · injectable product unapproved

GHK-Cu (Copper Peptide)

Legal cream with modest data. The injected version people sell has zero human trials.

Also searched as: copper peptide · copper peptides

Open the evidence file →

Completed evidence fileNot FDA-approved · active phase 3 development does not change status

Ibutamoren / MK-677

Human trials show endocrine target engagement and selected body-composition changes without consistent clinical benefit; important safety signals remain.

Also searched as: MK-677 · MK-0677 · MK0677 · LUM-201 · ibutamoren · ibutamoren mesylate

Open the evidence file →

Completed evidence fileDistinct from approved mecasermin · exact U.S. status not established

IGF-1 LR3

Animal, cell, and product-analysis records do not establish human muscle, recovery, performance, cognition, anti-aging, or safety claims.

Also searched as: long R3 IGF-1 · Long R3 IGF-I · Long-(Arg3)insulin-like growth factor-I

Open the evidence file →

Completed evidence filePCAC recommended inclusion · FDA final action pending

KPV

Preclinical anti-inflammatory findings; FDA identified no human exposure data through any route.

Also searched as: KPV peptide

Open the evidence file →

Completed evidence fileFDA-approved products for specific indications

Liraglutide

Large weight and cardiovascular trials make it foundational—not interchangeable with every product bearing its name.

Also searched as: Saxenda · Victoza

Open the evidence file →

Completed evidence fileNo FDA-approved U.S. product

Mazdutide

Positive phase 3 evidence in China does not become U.S. approval or online-product equivalence.

Also searched as: IBI362

Open the evidence file →

Completed evidence fileNot FDA-approved

Melanotan II

Visible tanning is not proof of safety. FDA records describe an unapproved substance and serious safety signals.

Also searched as: melanotan 2 · tanning peptide · the tanning one

Open the evidence file →

Completed evidence filePCAC recommended inclusion · FDA final action pending

MOTS-c

Human studies measure the body's own MOTS-c. FDA identified no studies administering it to people.

Also searched as: MOTS-c peptide

Open the evidence file →

Completed evidence fileFDA-approved injectable products for specific obstetric uses

Oxytocin

Approved injectable obstetric uses do not establish intranasal bonding, relationship, sexual-wellness, or autism treatment claims.

Also searched as: Pitocin · synthetic oxytocin · love hormone

Open the evidence file →

Completed evidence fileInvestigational · not FDA-approved

Retatrutide / “Reta”

A phase 3 diabetes trial is published; TRIUMPH-1 obesity is completed with no registry results posted. Retatrutide is still investigational.

Also searched as: retatrutide · Reta

Open the evidence file →

Completed evidence fileWithdrawn compounding nomination · safety information incomplete

Selank

Small active-comparator and adjunctive studies exist, but no modern placebo-controlled efficacy record or complete safety profile was identified.

Also searched as: Selank acetate · Selank diacetate · TP-7 · anxiety peptide · nootropic peptide

Open the evidence file →

Completed evidence fileFDA-approved products for specific indications

Semaglutide

Strong human evidence for specific approved products. An unrelated online vial does not inherit that evidence.

Also searched as: Wegovy · Ozempic

Open the evidence file →

Completed evidence filePCAC recommended inclusion · FDA final action pending

Semax

Small intranasal studies exist. They do not establish benefit or safety for the injectable products promoted online.

Also searched as: Semax peptide · focus peptide

Open the evidence file →

Completed evidence fileHistorical product discontinued · no current anti-aging approval

Sermorelin

Historical Geref approval is real. It is not a current anti-aging approval or proof that a different product is equivalent.

Also searched as: sermorelin acetate

Open the evidence file →

Completed evidence fileFDA-approved products for defined deficiency indications

Somatropin / HGH

Approved replacement uses do not establish general anti-aging, bodybuilding, recovery, or performance benefits.

Also searched as: HGH · human growth hormone · recombinant human growth hormone · rhGH

Open the evidence file →

Completed evidence filePCAC recommended inclusion · FDA final action pending

TB-500 (Thymosin Beta-4)

The “Wolverine peptide” claim still outruns the human evidence. PCAC recommended inclusion; FDA final action remains pending.

Also searched as: thymosin beta-4 fragment · recovery peptide

Open the evidence file →

Completed evidence fileNarrow FDA approval

Tesamorelin

A real FDA approval for excess abdominal fat in adults with HIV and lipodystrophy—not general weight loss.

Also searched as: Egrifta

Open the evidence file →

Completed evidence fileNot FDA-approved in the United States

Thymosin alpha-1

Human research exists, but “immune boost” overstates it; a 1,106-person sepsis trial found no mortality benefit.

Also searched as: TA1 · thymalfasin

Open the evidence file →

Completed evidence fileFDA-approved products for specific indications

Tirzepatide (Mounjaro / Zepbound)

The control group for this whole library: 2,500-person RCTs, ~20% weight loss, FDA-approved.

Also searched as: Zepbound · Mounjaro

Open the evidence file →

No completed evidence file matches that search or guided route. The name may still appear in the separate research roadmap below.

Researching · coverage roadmap

These 22 names are visible because PepCurrent is building toward mature coverage. None is a completed profile. No summary, evidence tier, safety conclusion, or FDA-status conclusion is being published here.

No evidence file yet: each name must clear identity verification, official-source review, human-evidence review, safety and product-quality checks, vault drafting, independent second-source review, generation, and QA before it can move above.